share_log

Bright Minds Is Unaware of Any Material Changes

Bright Minds Is Unaware of Any Material Changes

灵感博学对任何重大变化均不知情
newsfile ·  10/16 09:09

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity.

不列颠哥伦比亚省温哥华--(Newsfile Corp.,2024年10月15日)——应CIRO的要求,Bright Minds Biosciences Inc.(CSE:DRUG)(纳斯达克股票代码:DRUG)(“Bright Minds” 或 “公司”)希望确认公司管理层不知道公司运营中存在任何可能导致最近市场活动增加的重大变化。

About Bright Minds

关于 Bright M

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first- generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine.

Bright Minds专注于开发针对神经精神疾病、癫痫和疼痛的新型变革性疗法。Bright Minds拥有下一代血清素激动剂产品组合,旨在靶向导致难治性癫痫、耐药性抑郁症、创伤后应激障碍和疼痛等难以治疗的疾病的神经回路异常。该公司利用其世界一流的科学和药物开发专业知识来开发下一代安全有效的药物。Bright Minds的药物旨在潜在地保留迷幻药和其他血清素能化合物的强大治疗特性,同时最大限度地减少副作用,从而创造出比芬氟拉明、迷幻药、迷幻药和伊博加因等第一代化合物更好的药物。

Investor Contact:

投资者联系人:

Ian McDonald
CEO and Director
E: ian@brightmindsbio.com
T: (647) 865-8622

伊恩麦克唐纳
首席执行官兼董事
E: ian@brightmindsbio.com
电话:(647) 865-8622

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

加拿大证券交易所既没有批准也没有反对本新闻稿的内容。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发